



## **New Appointees Help Solidify Board**

**Singapore & Sydney: 11 September 2006.** The Board of Directors of SciGen Limited (ASX:SIE), has today announced that Mr. Saul Mashaal has been appointed Executive Chairman and C.E.O. of SciGen Limited. Mr. Mashaal was elected by the Board of Directors to the position of Executive Chairman in addition to his position as the C.E.O. of the Company.

Stepping down from his role as Chairman, Mr. Paul Freiman will remain on the SciGen Board as a Non-Executive Director. Under Mr. Freiman's Chairmanship the Board have benefited from his vast experience and leadership. His contribution to the Company was extremely helpful in the critical stages of its development. SciGen will continue to enjoy Mr. Freiman's strong leadership in his new role as Non-Executive Director.

Also elected was Mr. Ryszard K Krauze to the position of Non-Executive Vice Chairman of the Company. Mr. Krauze is the chairman of the Supervisory Board of Bioton S.A., SciGen's Strategic partner and one of the largest biotechnological companies in Central and Eastern Europe. Mr. Krauze is also the founder, key shareholder and president of Prokom Software, the largest IT group in Central and Eastern Europe. His appointment is a key component of the current restructure of the SciGen Board in continued effort to accelerate the growth of the Company.

### **About SciGen**

SciGen Ltd is a biopharmaceutical company involved in commercialising later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

**Further information:**

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)